Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Q3 net loss widens to $108.9 million on $10.0 million revenue

Mixed Impact 3 of 5 earnings Written later

Zenas BioPharma reported results for the quarter ended September 30, 2026. Revenue was $10.0 million, tied to a development milestone under its Bristol-Myers Squibb agreement, compared with none a year earlier. The net loss widened to $108.9 million, or $1.65 per share, from $51.5 million, or $1.22 per share, as research, development and administrative costs rose.

Key points

  • Revenue was $10.0 million, from a development milestone under the Bristol-Myers Squibb license and collaboration agreement; no revenue was recognized in the prior-year quarter.
  • Net loss was $108.9 million, or $1.65 per share, versus $51.5 million, or $1.22 per share, a year earlier.
  • R&D expenses were $58.5 million (up from $34.4 million) and G&A expenses were $27.4 million (up from $13.2 million).
  • Cash, cash equivalents and investments were $647.1 million as of September 30, 2026; the FDA set a PDUFA target action date of May 27, 2027 for obexelimab in IgG4-RD.

The filing

CompanyZenas BioPharma, Inc. (ZBIO)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:09 AM ET
Accession number0001104659-26-123035

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.